Udo Johannes Vetter
Director/Board Member presso GERRESHEIMER AG
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Axel Herberg | M | 66 |
Vetter Pharma-Fertigung GmbH & Co. KG
Vetter Pharma-Fertigung GmbH & Co. KG Miscellaneous Commercial ServicesCommercial Services For more than 25 years, Vetter Pharma-Fertigung has been synonymous with high quality aseptically pre-filled application systems. As a strategic partner, the company supports clients from the pharmaceutical and biotechnology industries in every phase of production, from product development through to successful product launches and commercial manufacturing. The firm is an independent company without any pharmaceutical products on the market. This means it can guarantee its partners absolute loyalty - as a conflict of interests is impossible right from the start. The company is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. The company employs about 1,900 people world-wide and holds nearly 140 patents. Vetter boasts longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities. Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions' patented application systems enable clients to compete more effectively throughout the world. | 10 anni |
Srinivas Sadu | M | 55 | 24 anni | |
Oliver Buck | M | - |
ITM Isotope Technologies Munich SE
ITM Isotope Technologies Munich SE Pharmaceuticals: MajorHealth Technology ITM Isotope Technologies Munich SE is a German radiopharmaceutical biotech company that specializes in providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians, and partners. ITM Isotope Technologies Munich is based in Garching, DE, and has subsidiaries in Germany. The company aims to provide a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company benefits from its GMP infrastructure and expertise in sourcing, processing, and radiolabeling. The company was founded in 2004, and Steffen Schuster has been the CEO of the company since 2011.
ITM Isotopen Technologien München AG
ITM Isotopen Technologien München AG Miscellaneous Commercial ServicesCommercial Services ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany.
International Centers for Precision Oncology Foundation
| 19 anni |
Pallerlamudi Sampath Kumar | M | - | 14 anni | |
Michael Lee-Chin | M | 73 |
ITM Isotopen Technologien München AG
ITM Isotopen Technologien München AG Miscellaneous Commercial ServicesCommercial Services ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany.
ITM Isotope Technologies Munich SE
ITM Isotope Technologies Munich SE Pharmaceuticals: MajorHealth Technology ITM Isotope Technologies Munich SE is a German radiopharmaceutical biotech company that specializes in providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians, and partners. ITM Isotope Technologies Munich is based in Garching, DE, and has subsidiaries in Germany. The company aims to provide a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company benefits from its GMP infrastructure and expertise in sourcing, processing, and radiolabeling. The company was founded in 2004, and Steffen Schuster has been the CEO of the company since 2011.
International Centers for Precision Oncology Foundation
| 5 anni |
Gunther Strothe | M | - |
ITM Isotopen Technologien München AG
ITM Isotopen Technologien München AG Miscellaneous Commercial ServicesCommercial Services ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany.
RV Invest GmbH
RV Invest GmbH Investment ManagersFinance RV Invest GmbH provides business and economic services. The private company is based in Ravensburg, Germany. The CEOs are Udo Johannes Vetter, Gunther Strothe, Wolfgang Kerkhoff. The German company was founded in 2016.
ITM Isotope Technologies Munich SE
ITM Isotope Technologies Munich SE Pharmaceuticals: MajorHealth Technology ITM Isotope Technologies Munich SE is a German radiopharmaceutical biotech company that specializes in providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians, and partners. ITM Isotope Technologies Munich is based in Garching, DE, and has subsidiaries in Germany. The company aims to provide a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company benefits from its GMP infrastructure and expertise in sourcing, processing, and radiolabeling. The company was founded in 2004, and Steffen Schuster has been the CEO of the company since 2011. | 8 anni |
C. S. Venkatesan | M | - | 26 anni | |
Robert Froehler | M | 64 | 2 anni | |
Shilpi Sahay | M | - | 10 anni | |
Surapanini Sridevi | M | - | 22 anni | |
Cordula Niehuis | M | - | - | |
Manuel Salvisberg | M | - |
ITM Isotopen Technologien München AG
ITM Isotopen Technologien München AG Miscellaneous Commercial ServicesCommercial Services ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany.
ITM Isotope Technologies Munich SE
ITM Isotope Technologies Munich SE Pharmaceuticals: MajorHealth Technology ITM Isotope Technologies Munich SE is a German radiopharmaceutical biotech company that specializes in providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians, and partners. ITM Isotope Technologies Munich is based in Garching, DE, and has subsidiaries in Germany. The company aims to provide a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company benefits from its GMP infrastructure and expertise in sourcing, processing, and radiolabeling. The company was founded in 2004, and Steffen Schuster has been the CEO of the company since 2011. | - |
Marlis Mergenthal | F | 38 | 2 anni | |
Essaji Goolam Vahanvati | M | - | 4 anni | |
Paul Schilling | M | 54 | 7 anni | |
Katja Mögel-Schnitzler | F | 43 | 8 anni | |
Ueli Utzinger | M | - | 3 anni | |
Markus Rocholz | M | 54 | 12 anni | |
Satyanaraynna Murthy Chavali | M | 57 | 6 anni | |
Ashish Adhikari | M | - | 5 anni | |
Andrea Abt | F | 64 | 9 anni | |
Annette Koehler | M | 57 | 2 anni | |
Qi Yu Chen | M | 52 | 7 anni | |
Yiu Kwan Lau | M | 69 | 5 anni | |
Peter Michael Noé | M | 67 | 12 anni | |
Francesco Grioli | M | 52 | 13 anni | |
Steffen Schuster | M | 59 |
ITM Isotopen Technologien München AG
ITM Isotopen Technologien München AG Miscellaneous Commercial ServicesCommercial Services ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany.
ITM Isotope Technologies Munich SE
ITM Isotope Technologies Munich SE Pharmaceuticals: MajorHealth Technology ITM Isotope Technologies Munich SE is a German radiopharmaceutical biotech company that specializes in providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians, and partners. ITM Isotope Technologies Munich is based in Garching, DE, and has subsidiaries in Germany. The company aims to provide a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company benefits from its GMP infrastructure and expertise in sourcing, processing, and radiolabeling. The company was founded in 2004, and Steffen Schuster has been the CEO of the company since 2011. | 13 anni |
Karin Louise Dorrepaal | M | 63 | 12 anni | |
Naina Lal Kidwai | F | 67 | 3 anni | |
Fang Yao | M | 54 | 2 anni | |
Odile Jaume | F | - |
International Centers for Precision Oncology Foundation
| - |
Taranjit Singh | M | - |
International Centers for Precision Oncology Foundation
| - |
Rong Wu | M | - | - | |
Jia Ai Zhang | M | - | 3 anni | |
Nicholas H. Vetter | M | - |
OncoBeta GmbH
OncoBeta GmbH Medical SpecialtiesHealth Technology OncoBeta GmbH is a privately held medical device company based in Garching near Munich, Germany. The German company specializes in the development and commercialization of innovative therapies, particularly the epidermal radioisotope therapy Rhenium-SCT® for non-melanoma skin cancers and keloid scars. OncoBeta was founded in 2010 by Oliver Buck and Doris Zur Muehlen, and the CEO is Shannon D. Brown. | - |
Shannon D. Brown | M | - |
OncoBeta GmbH
OncoBeta GmbH Medical SpecialtiesHealth Technology OncoBeta GmbH is a privately held medical device company based in Garching near Munich, Germany. The German company specializes in the development and commercialization of innovative therapies, particularly the epidermal radioisotope therapy Rhenium-SCT® for non-melanoma skin cancers and keloid scars. OncoBeta was founded in 2010 by Oliver Buck and Doris Zur Muehlen, and the CEO is Shannon D. Brown. | - |
Guido Pickert | M | - | - | |
Thomas Otto | M | - |
Vetter Pharma-Fertigung GmbH & Co. KG
Vetter Pharma-Fertigung GmbH & Co. KG Miscellaneous Commercial ServicesCommercial Services For more than 25 years, Vetter Pharma-Fertigung has been synonymous with high quality aseptically pre-filled application systems. As a strategic partner, the company supports clients from the pharmaceutical and biotechnology industries in every phase of production, from product development through to successful product launches and commercial manufacturing. The firm is an independent company without any pharmaceutical products on the market. This means it can guarantee its partners absolute loyalty - as a conflict of interests is impossible right from the start. The company is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. The company employs about 1,900 people world-wide and holds nearly 140 patents. Vetter boasts longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities. Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions' patented application systems enable clients to compete more effectively throughout the world. | 29 anni |
Richard P. Baum | M | - |
International Centers for Precision Oncology Foundation
| - |
Ravi Shekhar Mitra | M | - | 5 anni | |
Bernd Metzner | M | 53 | 5 anni | |
Dietmar Siemssen | M | 60 | 6 anni | |
Wolfgang Kerkhoff | M | - |
RV Invest GmbH
RV Invest GmbH Investment ManagersFinance RV Invest GmbH provides business and economic services. The private company is based in Ravensburg, Germany. The CEOs are Udo Johannes Vetter, Gunther Strothe, Wolfgang Kerkhoff. The German company was founded in 2016. | 6 anni |
Lukas Burkhardt | M | 45 | 6 anni | |
Peter Sölkner | M | - |
Vetter Pharma-Fertigung GmbH & Co. KG
Vetter Pharma-Fertigung GmbH & Co. KG Miscellaneous Commercial ServicesCommercial Services For more than 25 years, Vetter Pharma-Fertigung has been synonymous with high quality aseptically pre-filled application systems. As a strategic partner, the company supports clients from the pharmaceutical and biotechnology industries in every phase of production, from product development through to successful product launches and commercial manufacturing. The firm is an independent company without any pharmaceutical products on the market. This means it can guarantee its partners absolute loyalty - as a conflict of interests is impossible right from the start. The company is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. The company employs about 1,900 people world-wide and holds nearly 140 patents. Vetter boasts longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities. Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions' patented application systems enable clients to compete more effectively throughout the world. | 16 anni |
Bent Reichardt | M | - |
ITM Isotopen Technologien München AG
ITM Isotopen Technologien München AG Miscellaneous Commercial ServicesCommercial Services ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany. | - |
Joachim del Boca | M | - |
Vetter Pharma-Fertigung GmbH & Co. KG
Vetter Pharma-Fertigung GmbH & Co. KG Miscellaneous Commercial ServicesCommercial Services For more than 25 years, Vetter Pharma-Fertigung has been synonymous with high quality aseptically pre-filled application systems. As a strategic partner, the company supports clients from the pharmaceutical and biotechnology industries in every phase of production, from product development through to successful product launches and commercial manufacturing. The firm is an independent company without any pharmaceutical products on the market. This means it can guarantee its partners absolute loyalty - as a conflict of interests is impossible right from the start. The company is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. The company employs about 1,900 people world-wide and holds nearly 140 patents. Vetter boasts longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities. Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions' patented application systems enable clients to compete more effectively throughout the world. | - |
Hermann Piana | M | - |
Vetter Pharma-Fertigung GmbH & Co. KG
Vetter Pharma-Fertigung GmbH & Co. KG Miscellaneous Commercial ServicesCommercial Services For more than 25 years, Vetter Pharma-Fertigung has been synonymous with high quality aseptically pre-filled application systems. As a strategic partner, the company supports clients from the pharmaceutical and biotechnology industries in every phase of production, from product development through to successful product launches and commercial manufacturing. The firm is an independent company without any pharmaceutical products on the market. This means it can guarantee its partners absolute loyalty - as a conflict of interests is impossible right from the start. The company is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. The company employs about 1,900 people world-wide and holds nearly 140 patents. Vetter boasts longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities. Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions' patented application systems enable clients to compete more effectively throughout the world. | 20 anni |
Sumanta Bajpayee | M | - | 4 anni | |
Oskar Gold | M | - |
Vetter Pharma-Fertigung GmbH & Co. KG
Vetter Pharma-Fertigung GmbH & Co. KG Miscellaneous Commercial ServicesCommercial Services For more than 25 years, Vetter Pharma-Fertigung has been synonymous with high quality aseptically pre-filled application systems. As a strategic partner, the company supports clients from the pharmaceutical and biotechnology industries in every phase of production, from product development through to successful product launches and commercial manufacturing. The firm is an independent company without any pharmaceutical products on the market. This means it can guarantee its partners absolute loyalty - as a conflict of interests is impossible right from the start. The company is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. The company employs about 1,900 people world-wide and holds nearly 140 patents. Vetter boasts longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities. Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions' patented application systems enable clients to compete more effectively throughout the world. | - |
Martin Bosch | M | - |
International Centers for Precision Oncology Foundation
| - |
Tadd Seaton Wessel | M | - |
ITM Isotope Technologies Munich SE
ITM Isotope Technologies Munich SE Pharmaceuticals: MajorHealth Technology ITM Isotope Technologies Munich SE is a German radiopharmaceutical biotech company that specializes in providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians, and partners. ITM Isotope Technologies Munich is based in Garching, DE, and has subsidiaries in Germany. The company aims to provide a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company benefits from its GMP infrastructure and expertise in sourcing, processing, and radiolabeling. The company was founded in 2004, and Steffen Schuster has been the CEO of the company since 2011. | 3 anni |
Stefan Sanktjohanser | M | - |
ITM Isotope Technologies Munich SE
ITM Isotope Technologies Munich SE Pharmaceuticals: MajorHealth Technology ITM Isotope Technologies Munich SE is a German radiopharmaceutical biotech company that specializes in providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians, and partners. ITM Isotope Technologies Munich is based in Garching, DE, and has subsidiaries in Germany. The company aims to provide a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company benefits from its GMP infrastructure and expertise in sourcing, processing, and radiolabeling. The company was founded in 2004, and Steffen Schuster has been the CEO of the company since 2011. | 4 anni |
Marion Stolzenwald | F | 64 | 13 anni | |
Manish Bharadwaj | M | - | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Theodor Stuth | M | 71 | 14 anni | |
Christian Fischer | M | 60 | 1 anni | |
Sonja Apel | F | 57 | 9 anni | |
Rainer Beaujean | M | 56 | 7 anni | |
Jens Kürten | M | 55 | 12 anni | |
Burkhard Lingenberg | M | - | - | |
Moheb Ali Mohammed | M | 80 | - | |
Prakash Vithal Baliga | M | - | 8 anni | |
Susheel Ogra | M | - | 7 anni | |
Severine Camp | F | - | - | |
Heike Arndt | F | 61 | 4 anni | |
Nicole Winkler | F | - | - | |
K. V. G. K. Raju | M | - | 32 anni | |
Eugen Heinz | M | 64 | - | |
Stefan Grote | M | 55 | 1 anni | |
Yi Fang Wu | M | 54 | 2 anni | |
Franz Hartinger | M | 64 | - | |
Douglas E. Rogers | M | 66 | 3 anni | |
Xiao Hui Guan | F | 53 | 3 anni | |
Harald Sikorski | M | 58 | 5 anni | |
Gerhard Prante | M | 82 | 5 anni | |
Reiner Ludwig | M | - | 5 anni | |
Günther Fehn | M | - | 5 anni | |
Lydia Armer | F | 65 | - | |
Gottlieb Förster | M | - | - | |
Gerhard Schulze | M | 80 | 7 anni | |
Hans Peter Peters | M | 80 | 7 anni | |
Max Raster | M | 59 | - | |
Lionel Yves Assant | M | 52 | - | |
Andreas Schütte | M | 62 | 10 anni | |
Seppel Kraus | M | 71 | 5 anni | |
Hans-Jürgen Elmar Wiecha | M | 62 | 13 anni | |
Uwe Ferdinand Röhrhoff | M | 62 | 26 anni | |
Dong Ming Li | M | 55 | 3 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Germania | 65 | 73.03% |
India | 24 | 26.97% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Udo Johannes Vetter
- Contatti personali